{
  "docId": "019de076-f8dc-71cb-8c77-d8d892e68e05",
  "docSlug": "d63a60a343bcaadeb9fd5627a42c66c9",
  "documentTitle": "CARGO Therapeutics | IPO Presentation Deck | 29 slides",
  "authorId": "cargo-therapeutics",
  "authorName": "CARGO Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7794254,
  "pageNumber": 14,
  "pageCount": 29,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "peer_benchmark",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 32,
  "notes": "The slide uses a comparison table to contrast clinical trial data for CRG-022 against historical benchmarks for ZUMA-1, JULIET, and TRANSCEND.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/14",
  "deckHref": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05",
  "deckJsonHref": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json",
  "deckAnchorHref": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.2,
        "x": 0.78,
        "y": 0.3
      },
      "kind": "callout",
      "text": "IEC-HS incidence: DL1: 7%, DL2: 33%, Total: 18%. Managed with anakinra and steroids. Real world incidence of carHLH with CD19 CARs: Peds B-ALL: 14.8%, DLBCL: 6%",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3ee5cb3c-4783-417a-8457-81459432bc5a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.04,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Abbreviations: IEC-HS = Immune effector cell HLH-like syndrome; carHLH = Chimeric Antigen Receptor T-Cell-Associated Hemophagocytic Lymphohistiocytosis. Source: (1) Hines et al. 2021; (2) Ahmed et al. 2020; (3) Data reported from clinical studies for each approved therapy and not from head-to-head studies with CRG-022.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "23b7cb80-7f9c-4546-966f-b8e084b29740",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.75,
        "x": 0.04,
        "y": 0.23
      },
      "kind": "table",
      "text": "Cytokine Release Syndrome and Neurologic Events/ICANS data for DL1, DL2, and Total cohorts compared to ZUMA-1, JULIET, and TRANSCEND.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee46906a-0ba0-40c1-9ba8-379778578872",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.04,
        "y": 0.08
      },
      "kind": "title",
      "text": "Phase 1 – CRG-022 was generally well-tolerated",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6bb29cfd-30c3-478f-a142-9bfc7ca3ca01",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "dc7f75cc-612f-4e02-a3fa-ef61433df054",
      "evidence": "table/data: Cytokine Release Syndrome and Neurologic Events/ICANS data for DL1, DL2, and Total cohorts compared to ZUMA-1, JULIET, and TRANSCEND.",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "458a23d7-f031-4a5b-956b-0b1593bca8a5",
      "evidence": "Direct comparison of clinical trial safety data against historical benchmarks for approved therapies.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 15,
      "from": 12,
      "beatId": "2e0a910a-dd04-43c7-b080-55652ca53d9d",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Slides 12-15 present traction and results",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 15,
      "from": 10,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "1e639289-7657-46f8-9306-fe7898bf6a06",
      "evidence": "The loop is opened on slide 10 and closed on slides 12-15",
      "position": 0,
      "objective": "What is the cost of not addressing the unmet need for LBCL patients whose disease is R/R to CD19 CAR T-cell therapy?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 28,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "f28bc1f0-250a-416d-b5fe-d9a40f469b97",
      "evidence": "The loop is opened on slide 4 and closed on slide 28",
      "position": 1,
      "objective": "Why does CARGO Therapeutics exist? What is the company's vision?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}